Moleculin Biotech (MBRX) Cash from Financing Activities (2016 - 2025)

Moleculin Biotech's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $7.5 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities rose 748600.0% year-over-year to $7.5 million; the TTM figure through Dec 2025 stood at $27.3 million (up 488.65% YoY), while the FY2025 annual figure was $27.3 million, up 488.65% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $7.5 million, up from $6.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $74.7 million in Q1 2021, with the low at -$25000.0 in Q2 2024.
• The 5-year median for Cash from Financing Activities is $141000.0 (2023), against an average of $7.4 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities slumped 151.02% in 2024, then soared 748600.0% in 2025.
• Moleculin Biotech's Cash from Financing Activities stood at -$24000.0 in 2021, then surged by 54.17% to -$11000.0 in 2022, then soared by 36054.55% to $4.0 million in 2023, then slumped by 99.97% to $1000.0 in 2024, then jumped by 748600.0% to $7.5 million in 2025.
• Business Quant data shows MBRX's Cash from Financing Activities at $7.5 million in Q4 2025, $6.4 million in Q3 2025, and $5.4 million in Q2 2025.